Cambridge-based Carmine Therapeutics has officially inked a research collaboration with Takeda Pharmaceuticals to develop and commercialize non-viral gene therapies for two rare diseases.

This $900M deal will allow Takeda to option licensing both programs after preclinical proof-of-concept studies are concluded, before taking over clinical development and commercialization.